Paritaprevir, THE INITIAL Protease Inhibitor for HCV Infection
Paritaprevir is an NS3/4A protease inhibitor discovered during the ongoing collaboration between Enanta and AbbVie for HCV protease inhibitors and the first developed in AbbVie’s treatment regimens that include protease inhibitors.
Paritaprevir is one of the direct-acting-antivirals in VIEKIRA PAK and the other treatment regimens that AbbVie developed and has been marketing worldwide for HCV genotypes 1 and 4.
Glecaprevir, Enanta’s Second HCV Protease Inhibitor
Glecaprevir is the second protease inhibitor discovered within the Enanta-AbbVie collaboration.
Glecaprevir was designed to enable once-daily dosing without ritonavir or ribavirin. AbbVie has co-formulated it in a fixed-dose combination with AbbVie’s new NS5A inhibitor, pibrentasvir. The U.S. Food and Drug Administration has approved MAVYRET™ (glecaprevir/pibrentasvir) and the European Commission has granted AbbVie Marketing Authorization for MAVIRET™ (glecaprevir/pibrentasvir) in the E.U. MAVIRET™ (glecaprevir/pibrentasvir) has also been approved by the Japanese Ministry of Health, Labour and Welfare.